Clinical Trial Update: Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab [Phase 2]

View source ↗

Summary

An investigator-initiated Phase 2 trial evaluating the combination of ipilimumab, nivolumab, and stereotactic radiation for metastatic clear-cell renal cell car…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 2 | Status: WITHDRAWN